Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,501.65 0.00 0.00%
S&P 500 1,878.61 3.22 0.17%
NASDAQ 4,148.34 21.37 0.52%
Ticker Volume Price Price Delta
STOXX 50 3,189.81 13.84 0.44%
FTSE 100 6,703.00 28.26 0.42%
DAX 9,548.68 4.49 0.05%
Ticker Volume Price Price Delta
NIKKEI 14,553.78 148.79 1.03%
TOPIX 1,177.52 12.62 1.08%
HANG SENG 22,562.80 53.16 0.24%

Potential Buyouts, Stronger Pipelines, FDA Filings - Research Report on Keryx, Lilly, Baxter, Biogen Idec and Shire



Potential Buyouts, Stronger Pipelines, FDA Filings - Research Report on Keryx,
                     Lilly, Baxter, Biogen Idec and Shire

PR Newswire

NEW YORK, March 6, 2013

NEW YORK, March 6, 2013 /PRNewswire/ --

Today, Investors Alliance announced new research reports highlighting Keryx
Biopharmaceuticals (NASDAQ: KERX), Eli Lilly & Co. (NYSE: LLY), Baxter
International Inc. (NYSE: BAX), Biogen Idec Inc. (NASDAQ: BIIB) and Shire PLC
(NASDAQ: SHPG). Today's readers may access these reports free of charge -
including full price targets, industry analysis and analyst ratings - via the
links below.

Keryx Biopharmaceuticals Research Report

Shares for biopharmaceutical company Keryx popped by about 12 percent
following the rumor that GlaxoSmithKline may be interested in acquiring the
company. Neither Keryx nor GlaxoSmithKline has issued a statement on the
potential acquisition. If rumors fizzle out, however, investors for Keryx
still have a reason to rejoice. Earlier this year, Keryx reported the
successful results of a late-stage trial of its experimental drug for kidney
disease. The drug, called Zerenex, is a treatment for hyperphosphatemia in
patients with end-stage renal disease on dialysis. The company is planning to
file for regulatory approval in the United States in Europe in the second
quarter of 2013. The Full Research Report on Keryx Biopharmaceuticals -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.investors-alliance.com/r/full_research_report/5d72_KERX]

--

Eli Lilly & Co. Research Report

Eli Lilly highlights its autoimmune pipeline, especially baricitinib, a
treatment for patients with moderate-to-severe rheumatoid arthritis. It also
has a number of other drugs currently in its Phase III clinical development
pipeline, with four potential medicines for diabetes, three for cancer, two
for neuroscience, three for autoimmunity and one for cardiovascular disease.
At present, Lilly is adamantly defending its Erbitux drug, the FDA-approved
treatment for colon cancer and head and neck tumors, against Roche Holding's
complaint stating that the said drug infringes patents held by Roche's
Genentech unit. Lilly states that "it has no obligation to pay royalties on
the sale of Erbitux" because it did not infringe any patent. The company
intends to continue strengthening its pipeline in the future. The Full
Research Report on Eli Lilly & Co. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at: [http://www.investors-alliance.com/r/full_research_report/3739_LLY]

--

Baxter International Inc. Research Report

Investors for Baxter have a reason to celebrate after the company announced
that it has submitted a biologics license application (BLA) supplement to the
FDA for the approval of its hemophilia A or B drug. It is estimated that
17,000 people in the US have been diagnosed with hemophilia A or B,
representing the potential market for the new drug. Furthermore, the company's
acquisition of the investigational hemophilia compound from
BioPharmaceuticals, Inc. is also expected to reinforce the company's
hemophilia portfolio. With a strong pipeline and an increasingly growing
portfolio, many expect Baxter to be valuable in the long run. The Full
Research Report on Baxter International Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at:
[http://www.investors-alliance.com/r/full_research_report/b301_BAX]

--

Biogen Idec Inc. Research Report

Shares for Biogen Idec rose following news that Bristol-Myers Squibb is
interested in acquiring the company. However, neither Biogen Idec nor Bristol
decided to comment. Biogen Idec recently reported Phase 3 data on the
confirmed ability of investigational recombinant factors VIII Fc fusion
protein (rFVIIIFC) and IX Fc fusion protein (rFIXFc) to provide against
long-lasting protection from bleeding with fewer injections than required for
patients with hemophilia. Many have been commenting favorably on Biogen, with
analysts at Morgan Stanley increasing their price target on the company's
shares from $170 to $177. Analysts at Bank of America also raised their EPS on
the company's shares. The Full Research Report on Biogen Idec Inc. - including
full detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.investors-alliance.com/r/full_research_report/753b_BIIB]

--

Shire PLC Research Report

Shares for Shire also rose following the news that it is also a potential
target for Bristol. Shire has declined to comment on the issue. In
mid-February, the company was also reported as an ideal takeover target for
other biopharmaceutical companies including Teva. Reports suggest that Teva
would be interested in Shire's ADHD drugs. Moving forward, Shire has commented
that it is in "great shape," with its ADHD portfolio performing well and a
promising pipeline with new growth opportunities. The Full Research Report on
Shire PLC - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:
[http://www.investors-alliance.com/r/full_research_report/21cc_SHPG]

--

Consider Investors Alliance

Tired of hearing about the latest, greatest trade opportunity... only to
realize that the ship has long sailed? You need a strong, informative
community in your arsenal. Join the group that has been consistently
identifying momentous situations as they develop - long before they become the
next top news on major financial networks.

Contact: Patricia Byers
Email: press@Investors-Alliance.com
Main: +1-480-745-7826

SOURCE Investors-Alliance
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement